We are live on ! Find out more
DAWN icon

Day One Biopharmaceuticals

Delisted

DAWN was delisted on the 22nd of April, 2026.

147 hedge funds and large institutions have $1.2B invested in Day One Biopharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 48 increasing their positions, 42 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

41% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 17

14% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 42

6% more funds holding

Funds holding: 139 → 147 (+8)

1% more call options, than puts

Call options by funds: $1.31M | Put options by funds: $1.3M

4.7% less ownership

Funds ownership: 87.97% → 83.27% (-4.7%)

40% less capital inflows, than outflows

Capital inflows: $73.1M | Capital outflows: $123M

Holders
147
Holders Change
+8
Holders Change %
+5.76%
% of All Funds
2.11%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
24
Increased
48
Reduced
42
Closed
17
Calls
$1.31​M
Puts
$1.3​M
Net Calls
+$13​K
Net Calls Change
-⁠$1.07​M

DAWN Hedge Fund Activity: Q1 2024 in Review

147 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q1 2024, worth a combined $1.2B — up 7.5% from $1.12B a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new DAWN positions and 17 closed out — a net gain of 7 holders — while 48 added to existing stakes and 42 trimmed.

The largest buyer was Maverick Capital, opening a new position worth an estimated $18.8M. The largest seller was Braidwell, cutting an estimated $30.6M.

  • 147 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q1 2024, up from 139 in Q4 2023.
  • Funds reported $1.2B of Day One Biopharmaceuticals stock for Q1 2024, up 7.5% quarter-over-quarter.
  • 24 funds opened new Day One Biopharmaceuticals positions in Q1 2024 and 17 closed out, a net change of +7 holders.
  • The largest Day One Biopharmaceuticals buyer in Q1 2024 was Maverick Capital, an estimated $18.8M added.
  • The largest Day One Biopharmaceuticals seller in Q1 2024 was Braidwell, an estimated $30.6M sold.

Based on aggregated 13F filings for Q1 2024.